ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

Core Viewpoint - ACELYRIN, INC. is hosting a virtual investor event on January 6, 2025, to present updated Phase 2 data for lonigutamab, which shows promise for treating Thyroid Eye Disease (TED) with a potential best-in-class efficacy and safety profile [1] Company Overview - ACELYRIN, INC. is a late-stage clinical biopharma company focused on developing transformative medicines in immunology [1][11] - The company's lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting the IGF-1 receptor, currently being investigated for TED [11] Upcoming Event Details - The virtual investor event will feature presentations from ACELYRIN's CEO, CMO, and CCO, along with external clinician perspectives on TED [2] - A live Q&A session will follow the presentations, and a recording will be available on the company's website for approximately 30 days [2] Thyroid Eye Disease (TED) Insights - TED is a vision-threatening autoimmune disease affecting over 100,000 people in the U.S., characterized by inflammation and expansion of tissues behind the eye, leading to symptoms like proptosis and diplopia [8] Lonigutamab Characteristics - Lonigutamab is a humanized IgG1 monoclonal antibody that binds to the IGF-1 receptor, showing more potency in preclinical assays compared to standard care [9][10] - The subcutaneous delivery method allows for longer-term and convenient dosing, potentially improving clinical response durability [10]